The Effect of Cidofovir on Adenovirus Plasma DNA Levels in Stem Cell Transplantation Recipients without T Cell Reconstitution  Gertjan Lugthart, Marloes.

Slides:



Advertisements
Similar presentations
A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Advertisements

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.
Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.
Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation  Frans M. Verduyn Lunel,
Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome 
Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome  Joseph Delano F. Robles, Daniel.
Dynamics of Cytomegalovirus (CMV) Plasma DNAemia in Initial and Recurrent Episodes of Active CMV Infection in the Allogeneic Stem Cell Transplantation.
How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Patient, Virus, and Treatment-Related Risk Factors in Pediatric Adenovirus Infection after Stem Cell Transplantation: Results of a Routine Monitoring.
Vaccination of Children following Allogeneic Stem Cell Transplantation
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
Early Cytomegalovirus Reactivation Leaves a Specific and Dynamic Imprint on the Reconstituting T Cell Compartment Long-Term after Hematopoietic Stem Cell.
Gastrointestinal Acute Graft-versus-Host Disease in Children: Histology for Diagnosis, Mesenchymal Stromal Cells for Treatment, and Biomarkers for Prediction.
Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Treatment of Acyclovir-Resistant Herpes Simplex Virus with Continuous Infusion of High-Dose Acyclovir in Hematopoietic Cell Transplant Patients  Janet.
Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir  Dionissios Neofytos, Ambrish Ojha, Bijoyesh Mookerjee, John Wagner,
Allogeneic Stem Cell Transplantation in Myelofibrosis
Hematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation  Nina Cohen, Coralia N. Mihu, Susan.
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,
Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab  Laura.
Expansion of cytotoxic CD56bright natural killer cells during T-cell deficiency after allogeneic hematopoietic stem cell transplantation  Gertjan Lugthart,
Cardiac Chamber Hypertrophy following Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency  Sean R. Bulley, Lee Benson, Eyal Grunebaum,
Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation 
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
Sabina Kersting, Leo F. Verdonck 
Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes  J. Clausen, M. Enk, B. Vergeiner,
Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection.
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute 
High-Dose Weekly AmBisome Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study  Parinda.
Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources  Christopher M. Walker,
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma  Peter Dreger, Ginna.
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases  Elizabeth O. Stenger, Kuang-Yueh Chiang, Ann.
Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations During Conditioning for Hematopoietic Stem Cell Transplantation  Walter J.F.M.
B Cells and Transplantation: An Educational Resource
Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients  Irene Schmid, Daniel Stachel,
Population Pharmacokinetic Modeling of Thymoglobulin in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized.
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Efficacy of CD34+ Stem Cell Dose in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation after Total Body Irradiation  Anurag K.
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis  Jason.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Clinical Strategies to Enhance Posttransplant Immune Reconstitution
Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome 
Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation  Radojka M. Savic, Morton.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Blood and Marrow Transplant Handbook
Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation  Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.
High peripheral blood progenitor cell counts enable autologous backup before stem cell transplantation for malignant infantile osteopetrosis  C.G. Steward,
Thymoglobulin® Exposure Is Influencing CD4+ Immune Reconstitution As a Predictor for Improved Overall Survival in Pediatric Haematopoietic Cell Transplantation:
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Successful Immune Reconstitution Decreases Leukemic Relapse and Improves Survival in Recipients of Unrelated Cord Blood Transplantation  Robertson Parkman,
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Treatment versus Transplant for Challenging Hematologic Disorders
A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation  Mark H. Kirschbaum,
Mary Eapen  Biology of Blood and Marrow Transplantation 
In Memoriam: E. Donnall Thomas
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Optimal Donor Selection: Beyond HLA
Presentation transcript:

The Effect of Cidofovir on Adenovirus Plasma DNA Levels in Stem Cell Transplantation Recipients without T Cell Reconstitution  Gertjan Lugthart, Marloes A. Oomen, Cornelia M. Jol-van der Zijde, Lynne M. Ball, Dorine Bresters, Wouter J.W. Kollen, Frans J. Smiers, Clementien L. Vermont, Robbert G.M. Bredius, Marco W. Schilham, Maarten J.D. van Tol, Arjan C. Lankester  Biology of Blood and Marrow Transplantation  Volume 21, Issue 2, Pages 293-299 (February 2015) DOI: 10.1016/j.bbmt.2014.10.012 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 HAdV load dynamics in relation to T cell reconstitution. (A) Change of plasma human adenovirus DNA levels (HAdV load) between the start of treatment (day 0) and day 14 of cidofovir treatment in cases with T cell numbers <50 cells/μL (n = 20, left bar) and T cell numbers ≥50 cells/μL (n = 22, right bar) within this time period. HAdV load change: clearance: dashed, ≥1 log reduction: white, stabilization: gray, ≥1 log increase: black. P value: Pearson's chi-square test. (B) Change of HAdV load between day 0 and 14 in 22 cidofovir treatments with T cell numbers ≥50 cells/μL. Solid lines: cases without steroid treatment. Interrupted lines: methylprednisolone >1 mg/kg of body weight. Shaded area: HAdV load below limit of detection (1.7 log c/mL). (C) Change of T cell numbers between day 0 and 14 in 22 cidofovir treatments with T cell reconstitution. Solid lines: cases without steroid treatment. Interrupted lines: methylprednisolone >1 mg/kg of body weight. Shaded area: T cells below limit of detection (10 cells/μL). Biology of Blood and Marrow Transplantation 2015 21, 293-299DOI: (10.1016/j.bbmt.2014.10.012) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 HAdV control in the absence of T cells. (A-C) Plasma human HAdV DNA levels in 20 cidofovir treatments with T cell numbers <50 cells/μL. Follow-up was stopped at 1 week after the last dose of cidofovir or 1 week before T cell numbers reached 50 cells/μL. HAdV load change: ≥1 log reduction (A, n = 7), stabilization (B, n = 8) or ≥1 log increase (C, n = 5). Solid lines: cases with ≥5 fold NK cell expansion, interrupted lines: cases without NK cell expansion. Vertical dotted line: start of treatment. Shaded area: HAdV load below limit of detection (1.7 log c/mL). (D-F) Absolute numbers of NK cells in peripheral blood in cases with HAdV load reduction (D), stabilization (E) and increase (F). Solid lines: cases with ≥5 fold NK cell expansion, interrupted lines: cases without NK cell expansion. Identical symbols in corresponding figures represent individual cases. Vertical dotted line: start of treatment. Shaded area: NK cells below limit of detection (10 cells/μL). Biology of Blood and Marrow Transplantation 2015 21, 293-299DOI: (10.1016/j.bbmt.2014.10.012) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions